A reappraisal of the blood glucose homeostat which comprehensively explains the type 2 diabetes mellitus-syndrome X complex

Journal of Physiology

Volumn 549, Issue 2, 2003, Pages 333-346

  Koeslag, Johan H ^b   Saunders, Peter T ^a   Terblanche, Elmarie ^b  

^a STELLENBOSCH UNIVERSITY   (South Africa)

^b KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; CALCITONIN; CALCIUM ION; CHROMOGRANIN; GLUCAGON; GLUCOSE; GROWTH HORMONE; INSULIN; PARATHYROID HORMONE; SOMATOSTATIN 28; 4 AMINOBUTYRIC ACID; ADENOSINE TRIPHOSPHATE SENSITIVE POTASSIUM CHANNEL; GASTRIC INHIBITORY POLYPEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCOSE TRANSPORTER 2; HUMAN GROWTH HORMONE; LACTATE DEHYDROGENASE; PANCREASTATIN; SOMATOSTATIN 14;

CALCIUM BLOOD LEVEL; CARDIOVASCULAR DISEASE; DYSLIPIDEMIA; EXERCISE; GAP JUNCTION; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE INTOLERANCE; GLUCOSE TRANSPORT; GROWTH HORMONE BLOOD LEVEL; HUMAN; HYPERGLUCAGONEMIA; HYPERINSULINEMIA; HYPOTHALAMUS; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN RESPONSE; LACTATION; MEAL; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PANCREAS ISLET; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PARATHYROID GLAND; PRIORITY JOURNAL; PROTEIN SECRETION; REGULATORY MECHANISM; REVIEW; THYROID PARAFOLLICULAR CELL; ATHEROSCLEROSIS; BLOOD GLUCOSE MONITORING; CELL MEMBRANE DEPOLARIZATION; DESMOSOME; GLUCAGON RELEASE; GLUCOSE SENSOR; INSULIN RELEASE; INSULIN SYNTHESIS; NEGATIVE FEEDBACK; PANCREAS ISLET CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STEADY STATE; TIGHT JUNCTION;

EID: 0037497130     PISSN: 00223751     EISSN: None     Source Type: Journal    
DOI: 10.1113/jphysiol.2002.037895     Document Type: Review

References (142)

1. Adeghate E & Ponery AS (2002). GABA in the endocrine pancreas: cellular localisation and function in normal and diabetic rats. Tissue Cell 34, 1-6.
2. Adeghate E, Ponery AS, Pallot DJ & Singh J (2000). Distribution of neurotransmitters and their effects on glucagon secretion from in vitro normal and diabetic pancreatic tissues. Tissue Cell 32, 266-274.
3. Aguilar-Bryan L & Bryan J (1999). Molecular biology of adenosine triphosphate-sensitive potassium channels. Endocrinol Rev 20, 101-135.
4. Ahlborg B (1969). Blood glucose during prolonged physical exercise in man. Förvarsmed 3 (suppl 1), 85-99.
5. Ämmälä C, Ashcroft FM & Rorsman P (1993). Calcium-independent potentiation of insulin release by cyclic AMP in single β-cells. Nature 363, 356-358.
6. Arimura A, Sato H, Dupont A, Nishi N & Schally AV (1975). Somatostatin: abundance of immunoreactive hormone in rat stomach and pancreas. Science 189, 1007-1009.
7. Ashcroft FM, Proks P, Smith PA, Ämmälä C, Bokvist K & Rorsman P (1994). Stimulus-secretion coupling in pancreatic B cells. J Cell Biochem 55 (suppl 1), 54-65.
8. Asplin CM, Paquette TL & Palmer JP (1981). In vivo inhibition of glucagon secretion by paracrine beta cell activity in man. J Clin Invest 68, 314-318.
9. Aunis D & Metz-Boutigue M-H (2000). Chromogranins: current concepts. Structural and functional aspects. In Chromogranins, Functional and Clinical Aspects, ed. Helle KB & Aunis D, pp. 21-38. Kluwer Academic/Plenum, New York.
10. Baekkeskov S, Aanstoot H-J, Christgau S, Reetz S, Solimena M, Cascalho M, Folli F, Richter-Olesen H & Camilli P-D (1990). Identification of the 64K autoantigen in insulin-dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature 347, 151-156.
11. Baron AD, Schaeffer L, Shragg P & Kolterman OG (1987). Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36, 274-283.
12. Bell GI, Pilkins SJ, Weber IT & Polonsky KS (1996). Glucokinase mutations, insulin secretion, and diabetes mellitus. Ann Rev Physiol 58, 171-186.
13. 2+ and pancreatic b-cell function. Biochem Soc Trans 22, 12-18.
14. Berthoud HR, Kressel M & Neuhuber WL (1992). An anterograde tracing study of vagal innervation of rat liver, portal vein and biliary system. Anat Embryol 186, 431-442.
15. 2+ signalling. Diabetologia 32, 207-212.
16. Bolaffi JL, Heldt A, Lewis LD & Grodsky GM (1986). The third phase of in vitro insulin secretion. Evidence for glucose insensitivity. Diabetes 35, 370-373.
17. Bolli G, Defeo P, Compagnucci R, Cartechini MG, Angeletti G, Santeusanio F, Brunetti P & Gerich JE (1983). Abnormal glucose counterregulation in insulin dependent diabetes mellitus. Interaction of anti-insulin antibodies and impaired glucagon and epinephrine secretion. Diabetes 32, 134-141.
18. Bolli G, Tsalikian E, Haymond M, Cryer P & Gerich J (1984). Defective glucose counterregulation after subcutaneous insulin in non-insulin-dependent diabetes mellitus: paradoxical suppression of glucose utilization and lack of compensatory increase in glucose production; roles of insulin resistance, abnormal neuroendocrine responses and islet paracrine interactions. J Clin Invest 73, 1532-1541.
19. Bonner-Weir S (1991). Anatomy of the islets of Langerhans. In The Endocrine Pancreas, ed. Samols E, pp. 15-27. Raven, New York.
20. Brunicardi FC, Kleinman R, Moldovan S, Nguyen TH, Watt PC, Walsh J & Gingerich R (2001). Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet secretion in the isolated perfused human pancreas. Pancreas 23, 302-308.
21. Cannon WB (1960). The Wisdom of the Body. WW Norton, New York.
22. Carroll PV, Christ ER & The Members of the Growth Hormone Research Society Scientific Committee (1998). Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. J Clin Endocrinol Metab 83, 382-395.
23. Clynes M (1969). Cybernetic implications of rein control in perceptual and conceptual organization. Ann N Y Acad Sci 156, 629-690.
24. Coggan AR, Raguso CA, Williams BD, Sidossis LS & Gastaldelli A (1995). Glucose kinetics during high intensity exercise in endurance-trained and untrained humans. J Appl Physiol 78, 1203-1207.
25. Cooper GJS, Willis AC, Clark A, Turner RC, Sim RB & Reid KBM (1987). Purification and characterization of a peptide from amyloid-rich pancreases of type 2 diabetic patients. Proc Natl Acad Sci USA 84, 8628-8632.
26. Davis RJ (1993). The mitogen-activated protein kinase signal transduction pathway. J Biol Chem 268, 14553-14556.
27. Detimary P, Dejonghe S, Ling Z, Pipeleers D, Schuit F & Henquin JC (1998). The changes in adenine nucleotides measured in glucose-stimulated rodent islets occur in β-cells but not in α-cells, and are also observed in human islets. J Biol Chem 273, 33905-33908.
28. Dimitriadis GD, Pehling GB & Gerich JE (1985). Abnormal glucose modulation of islet A- and B-cell responses to arginine in non-insulin-dependent diabetes mellitus. Diabetes 34, 541-547.
29. Donovan CM, Halter JB & Bergman RN (1991). Importance of hepatic glucoreceptors in sympathoadrenal response to hypoglycaemia. Diabetes 40, 155-158.
30. Dunne MJ, Harding EA, Jaggar JH & Squires PE (1994). Ion channels and the molecular control of insulin secretion. Biochem Soc Trans 22, 6-12.
31. Felig P & Wahren J (1975). Fuel homeostasis in exercise. N Engl J Med 293, 1078-1084.
32. Garry DJ, Sorenson RL, Elde RP, Maley BE & Madsen A (1986). Immunohistochemical colocalization of GABA and insulin in β-cells of rat islets. Diabetes 35, 1090-1096.
33. Genuth SM (1993). Hormones of the pancreatic islets. In Physiology, ed. Berne RM & Levy MN, pp. 851-875. Mosby, St Louis.
34. Gerber JC & Hare TA (1980). GABA in peripheral tissues: presence and actions in pancreatic function. Brain Res Bull 5 (suppl 2), 341-346.
35. Gerich JE, Charles MA & Grodsky GM (1974). Characterization of the effects of arginine and glucose on glucagon and insulin release from the perfused rat pancreas. J Clin Invest 54, 833-841.
36. Gomez R, Asnis N, Tannhauser SL & Barros HM (1999). GABA agonists differentially modify blood glucose levels of diabetic rats. Jpn J Pharm 80, 327-331.
37. Grodsky GM (1972). A threshold distribution hypothesis for the package storage of insulin and its mathematical modeling. J Clin Invest 51, 2047-2059.
38. Guyton AC & Hall JE (1996). Textbook of Medical Physiology. WB Saunders, Philadelphia.
39. Hamilton-Wessler M, Bergman RN, Halter JB, Watanabe RM & Donovan CM (1994). The role of liver glucosensors in the integrated sympathetic response induced by deep hypoglycemia in dogs. Diabetes 43, 1052-1060.
40. Havel PJ, Veith RC, Dunning BE & Taborsky GJ (1991). Role for autonomic nervous system to increase pancreatic glucagon secretion during marked insulin-induced hypoglycemia in dogs. Diabetes 40, 1107-1114.
41. Hayden MR (2002). Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 diabetes mellitus. JOP 3, 126-138.
42. Heimberg H, De Vos A, Moens K, Quartier E, Bouwens L, Pipeleers D, Van Schaftingen E, Madsen O & Schuit F (1996). The glucose sensor protein glucokinase is expressed in glucagon-producing α-cells. Proc Natl Acad Sci U S A 93, 7036-7041.
43. Heimberg H, De Vos A, Pipeleers D, Thorens B & Schuit F (1995). Differences in glucose transporter gene expression between rat pancreatic α-and β-cells are correlated to differences in glucose transport but not in glucose utilization. J Biol Chem 270, 8971-8975.
44. Helle KB & Aunis D (2000). A physiological role for the granins as prohormones for homeostatically important regulatory peptides. In Chromogranins, Functional and Clinical Aspects, ed. Helle KB & Aunis D, pp. 389-397. Kluwer Academic/Plenum, New York.
45. Helle KB, Metz-Boutigue M-H & Aunis D (2001). Chromogranin A as a calcium-binding precursor for multiple regulatory peptides for the immune, endocrine and metabolic systems. Curr Med Chem 1, 119-140.
46. 2+ signalling and insulin release in human pancreatic beta cells. Diabetologia 37 (suppl 2), S11-S20.
47. Ipp E, Arimura A, Vale W, Harris V & Unger RH (1977). Release of immunoreactive somatostatin from the pancreas in response to glucose, amino acids, pancreozymin-cholecystokinin, and tolbutamide. J Clin Invest 60, 760-765.
48. Ishihara H, Maekler P, Gjinovci A, Herrera PL & Wollheim CB (2003). Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. Nat Cell Biol 5, 330-335.
49. Ito K, Maruyama H, Hirose H, Kido K, Kataoka K & Saruta T (1995). Exogenous insulin dose-dependently suppresses glucopenia-induced glucagon secretion from perfused pancreas. Metabolism 44, 358-362.
50. Jaspan JB, Lever E, Polonsky KS & Van Cauter E (1986). In vivo pulsatility of pancreatic islet peptides. Am J Physiol 251, E215-226.
51. Kahn SE (2000). The importance of the β-cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 108 (6A), 2S-8S.
52. Kawai K, Orci L & Unger RH (1982). Circulating somatostatin acts on the islets of Langerhans by way of a somatostatin-poor compartment. Science 218, 477-478.
53. Kimura N, Schindler M, Kasai N & Kimura I (2001). Immunohistochemical localization of somatostatin receptor type 2A in rat and human tissue. Endocrinol J 48, 95-102.
54. Kipnis D (1969). Insulin secretion in diabetes mellitus. Ann Intern Med 69, 891-901.
55. Kjaer M, Kiens B, Hargreaves M & Richter EA (1991). Influence of active muscle mass on glucose homeostasis during exercise in humans. J Appl Physiol 71, 552-557.
56. Kjeldsen H, Hansen AP & Lundbaek K (1975). Twenty-four-hour serum growth hormone levels in maturity onset diabetics. Diabetes 24, 977-982.
57. Koeslag JH (1982). Post-exercise ketosis and the hormone response to exercise. Med Sci Sports Exer 14, 327-334.
58. Koeslag JH, Levinrad LI, Lochner J De V & Sive AA (1985). Post-exercise ketosis in post-prandial exercise. Effect of glucose and alanine ingestion in humans. J Physiol 358, 395-403.
59. Koeslag JH, Noakes TD & Sloan AW (1980). Postexercise ketosis. J Physiol 301, 79-90.
60. Koeslag JH, Noakes TD & Sloan AW (1982). The effects of alanine, glucose and starch ingestion on the ketosis produced by exercise and starvation. J Physiol 325, 363-376.
61. Koeslag JH, Saunders PT & Wessels JA (1997). Glucose homeostasis with infinite gain: further lessons from the Daisyworld Parable. J Endocrinol 154, 187-192.
62. Koeslag JH, Saunders PT & Wessels JA. (1999). The chromogranins and counter-regulatory hormones: do they make homeostatic sense? J Physiol 517, 643-649.
63. Laedtke T, Kjems L, Porksen N, Schmitz O, Veldhuis J, Kao PC & Butler PC (2000). Overnight inhibition of insulin secretion restores pulsatility and proinsulin/insulin ratio in type 2 diabetes. Am J Physiol Endocrinol Metab 279, E520-528.
64. Lang DA, Matthews DR, Burnett M & Turner RC (1981). Brief, irregular oscillations of basal insulin and glucose concentrations in diabetic man. Diabetes 30, 435-439.
65. Larrson H & Ahrén B (1996). Failure to adequately adapt reduced insulin sensitivity with increased insulin secretion in women with impaired glucose tolerance. Diabetologia 39, 1099-1107.
66. Larrson H & Ahrén B (2000). Glucose intolerance is predicted by low insulin secretion and high glucagon secretion: outcome of a prospective study of postmenopausal Caucasian women. Diabetologia 43, 194-202.
67. Lee ZSK, Chan JCN, Yeung VTF, Chow C-C, Lau MSW, Ko GTC, Li JKY, Cockram CS & Critchley JAJH (1999). Plasma insulin, growth hormone, cortisol, and central obesity among young Chinese type 2 diabetic patients. Diabetes Care 22, 1450-1457.
68. Liu D, Moberg E, Kollind M, Lins P-E & Adamson U (1991). A high concentration of circulating insulin suppresses the glucagon response to hypoglycemia in normal man. J Clin Endocrinol Metab 73, 1123-1128.
69. Magnuson MA & Shelton KD (1989). An alternative promoter in the glucokinase gene is active in the pancreatic β-cell. J Biol Chem 264, 15936-15942.
70. Mandarino L, Stenner D, Blanchard W, Nissen S, Gerich J, Ling N, Brazeau P, Bohlen P, Esch F & Guillemin R (1981). Selective effects of somatostatin-14, -25, and -28 on in vitro insulin and glucagon secretion. Nature 291, 76-77.
71. Markussis V, Beshyah SA, Fisher C, Sharp P, Nicolaides AN & Johnston DG (1992). Detection of premature atherosclerosis by high resolution ultrasonography in symptom-free hypopituitary adults. Lancet 340, 1188-1192.
72. Matschinsky FM, Glaser B & Magnuson MA (1998). Pancreatic β-cell glucokinase: closing the gap between theoretical concepts and experimental realities. Diabetes 47, 307-315.
73. Matthews DR, Hermansen K, Connolly AA, Gray D, Schmitz O, Clark A, Orskov H & Turner RC (1987). Greater in vivo than in vitro pulsatility of insulin secretion with synchronized insulin and somatostatin secretory pulses. Endocrinology 120, 2272-2278.
74. Meda P, Kohen E, Kohen C, Rabinovitch A & Orci L (1982). Direct communication of homologous and heterologous endocrine islet cells in culture. J Cell Biol 92, 221-226.
75. Meda P, Santos RM & Atwater I (1986). Direct identification of electrophysiologically monitored cells with intact mouse islets of Langerhans. Diabetes 35, 232-236.
76. Meigs JB (2002). Epidemiology of the metabolic syndrome. Am J Man Care 8, S283-S292.
77. Michaels RL & Sheridan JD (1981). Islet of Langerhans dye coupling among immunocytochemically distinct cell types. Science 214, 801-803.
78. Milsum JH (1966). Biological Control Systems Analysis. McGraw-Hill, New York.
79. Niijima A (1986). Neural control of blood glucose level. Jpn J Physiol 36, 827-841.
80. Nyholm B, Pøslash N, Juhl CB, Gravholt CH, Butler PC, Weeke J, Veldhuis JD, Pincus S & Schmitz O (2000). Assessment of insulin secretion in relatives of patients with type 2 (non-insulin-dependent) diabetes mellitus: evidence of early β-cell dysfunction. Metabolism 49, 896-905.
81. O'Meara NM, Sturis J, Van Cauter E & Polonsky KS (1993). Lack of control by glucose ultradian insulin secretory oscillations in impaired glucose tolerance and non-insulin-dependent diabetes mellitus. J Clin Invest 92, 262-271.
82. O'Rahilly S, Turner RC & Matthews DR (1988). Impaired pulsatile secretion in relatives of patients with non-insulin-dependent diabetes. N Engl J Med 318, 1225-1230.
83. Orci L (1976). The microanatomy of the islets of Langerhans. Metabolism 25 (suppl), 1303-1313.
84. Orci L, Malaisse-Lagae F, Ravazzola M, Rouiller C, Renold AE, Perrelet A & Unger RH (1975). A morphological basis for intercellular communication between A- and B-cells in the endocrine pancreas. J Clin Invest 56, 1066-1070.
85. Orci L & Unger RH (1975). Hypothesis: Functional subdivisions of the islets of Langerhans and the possible role of the insular D-cells. Lancet 2, 1243-1244.
86. Orci L, Unger RH & Renold AE (1973). Structural coupling between pancreatic islet cells. Experientia 29, 1015-1018.
87. Palti Y, David GB, Lachov E, Mida YH & Schatzberger R (1996). Islets of Langerhans generate wavelike electrical activity modulated by glucose concentration. Diabetes 45, 595-601.
88. Pepys MB, Herbert J, Hutchinson WL, Tennent GA, Lachmann HJ, Gallimore JR, Lorat LB, Bartfai T, Alanine A, Hertel C, Hoffmann T, Jacob-Roetne R, Norcross RD, Kemp JA, Yamamura K, Suzuki M, Taylor GW, Murray S, Thompson D, Purvis A, Kolstoe S, Wood SP & Hawkins PN (2002). Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis. Nature 417, 254-259.
89. Pipeleers DG (1992). Heterogeneity in pancreatic B-cell population. Diabetes 41, 777-781.
90. Pipeleers D, Kiekens R, Ling Z, Wilikens A & Schuit F (1994). Physiologic relevance of heterogeneity in the pancreatic beta-cell population. Diabetologia 37 (suppl 2), S57-S64.
91. Pipeleers DG, Schuit FC, In't Veld P, Maes E, Hooghe-Peters EL, Van De Winkel M & Gepts W (1985). Interplay of nutrients and hormones in the regulation of insulin release. Endocrinology 117, 824-833.
92. Powell AM, Sherwin RS & Shulman GI (1993). Impaired hormonal responses to hypoglycemia in spontaneously diabetic and recurrently hypoglycemic rats. J Clin Invest 92, 2667-2674.
93. 2+, cAMP and phospholipid-derived messengers in coupling mechanisms in insulin secretion. Physiol Rev 67, 1185-229.
94. Prentki M, Tornheim K & Corkey BE (1997). Signal transduction mechanisms in nutrient-induced insulin secretion. Diabetologia 40 (suppl 2), S32-S41.
95. Raskin P, Aydin I & Unger RH (1976). Effect of insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. Diabetes 25, 227-229.
96. Reaven G (2002). Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation 106, 286-288.
97. Reaven GM, Chen Y-DI, Golay A, Awislocki ALM & Jaspan JB (1987). Documentation of hyperglucagonaemia throughout the day in nonobese and obese patients with noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab 64, 106-110.
98. Reisine T & Bell GI (1995). Molecular properties of somatostatin receptors. Neuroscience 67, 777-790.
99. Riggs DS (1963). The Mathematical Approach to Physiological Problems. Williams & Wilkins, Baltimore.
100. Riggs DS (1970). Control Theory and Physiological Feedback Mechanisms. Williams & Wilkins, Baltimore.
101. Rorsman P, Ashcroft FM & Berggren P-O (1991). Regulation of glucagon release from pancreatic α-cells. Biochem Pharm 41, 1783-1790.
102. A-receptor chloride channels. Nature 341, 233-236.
103. 2+-dependent action potentials. J Gen Physiol 91, 223-242.
104. Rösen P & Rösen R (1998). The rationale for sympathetic modulation in NIDDM and the insulin resistance syndrome. Rev Contemp Pharmacother 9, 429-439.
105. Roy JY, Bongbélé J, Cardin S, Brisson GR & Lavoie J-M (1991). Effects of supramaximal exercise on blood glucose levels during subsequent exercise. Eur J Appl Physiol 63, 48-51.
106. Samols E & Stagner JL (1988). Intra-islet regulation. Am J Med 85, 31-35.
107. Saunders PT, Koeslag JH & Wessels JA (1998). Integral rein control in physiology. J Theor Biol 194, 163-173.
108. Saunders PT, Koeslag JH & Wessels JA (2000). Integral rein control in physiology II: a general model. J Theor Biol 206, 211-220.
109. Sawchenko PE & Friedman MI (1979). Sensory functions of the liver: a review. Am J Physiol 236, R5-20.
110. Schauder P, Mcintosh C, Arends J, Arnold R, Frerichs H & Cruetzfeldt W (1976). Somatostatin and insulin release from isolated rat pancreatic islets stimulated by glucose. FEBS Lett 68, 225-227.
111. Schmidt WE, Siegel EG & Creutzfeldt W (1985). Glucagon-like peptide-A but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28, 704-707.
112. Schmidt WE, Siegel EG, Lamberts R, Gallwitz B & Creutzfeldt W (1988). Pancreastatin: molecular and immunochemical characterization of a novel peptide in porcine and human tissues. Endocrinology 123, 1395-1404.
113. Schmitz O, Pøslash N & Nyholm B (1997). Disorderly and nonstationary insulin secretion in relatives of patients with NIDDM. Am J Physiol 272, E218-226.
114. Schuit FC, Derde MP & Pipeleers DG (1989). Sensitivity of rat pancreatic A and B cells to somatostatin. Diabetologia 32, 207-212.
115. Schuit F, De Vos A, Farfari S, Moens K, Pipeleers D, Brun T & Prentki M (1997). Metabolic fate of glucose in purified islet cells: glucose-regulated anaplerosis in β-cells. J Biol Chem 272, 18572-18579.
116. Schuit FC, Huypens P, Heimberg H & Pipeleers DG (2001). Perspective in diabetes: glucose sensing in pancreatic β-cells. A model for the study of other glucose-regulated cells in gut, pancreas, and hypothalamus. Diabetes 50, 1-11.
117. Schuit FC, In't Veld PA & Pipeleers DG (1988). Glucose stimulates proinsulin biosynthesis by a dose dependent recruitment of pancreatic beta cells. Proc Natl Acad Sci U S A 85, 3865-3869.
118. Schuit F, Moens K, Heimberg H & Pipeleers D (1999). Cellular origin of hexokinase in pancreatic islets. J Biol Chem 274, 32803-32809.
119. Schuit FC & Pipeleers DG (1986). Differences in adrenergic recognition by pancreatic A and B cells. Science 232, 875-877.
120. Sekine N, Cirulli V, Regazzi R, Brown LJ, Gine E, Tamarit-Rodriguez J, Girotti M, Marie S, MacDonald MJ, Wollheim CB & Rutter GA (1994). Low lactate dehydrogenase and high mitochondrial glycerol phosphate dehydrogenase in pancreatic β-cells: potential role in nutrient sensing. J Biol Chem 269, 4895-4902.
121. Smismans A, Schuit F & Pipeleers D (1997). Nutrient regulation of gamma-aminobutyric acid release from islet beta cells. Diabetologia 40, 1411-1415.
122. Solerte SB, Rondanelli M, Giacchero R, Stabile M, Lovati E, Cravello L, Pontiggia B, Vignati G, Ferrari E & Fioravanti M (1999). Serum glucagon concentration and hyperinsulinaemia influence renal haemodynamics and urinary protein loss in normotensive patients with central obesity. Int J Obes 23, 997-1003.
123. Srikant CB & Patel YC (1981). Receptor binding of somatostatin-28 is tissue specific. Nature 294, 259-260.
124. Stagner JI, Samols E & Weir GC (1980). Sustained oscillations of insulin, glucagon and somatostatin from the isolated canine pancreas during exposure to a constant glucose concentration. J Clin Invest 65, 939-942.
125. Starke AAR, Erhardt G, Berger M & Zimmerman H (1984). Elevated pancreatic glucagon in obesity. Diabetes 33, 277-280.
126. Sumida Y, Shima T, Shirayama K, Misaki M & Miyaji K (1994). Effects of hexoses and their derivatives on glucagon secretion from isolated perfused rat pancreas. Horm Metab Res 26, 222-225.
127. Tannenbaum GS, Ling N & Brazeau P (1982). SRIF-28 is longer acting and more selective than SRIF on pituitary and pancreatic hormone release. Endocrinology 111, 101-107.
128. Tsuchiyama S, Tanigawa K & Kato Y (1992). Impaired glucose priming of insulin from perfused pancreas in aged female rats. Proc Soc Exper Biol Med 201, 54-58.
129. Unger RH, Aguilar-Parado E, Müller WA & Eisentraut AM (1970). Studies of pancreatic alpha cell function in normal and diabetic subjects. J Clin Invest 49, 837-848.
130. Unger RH, Dobbs RE & Orci L (1978). Insulin, glucagon, and somatostatin secretion in the regulation of metabolism. Ann Rev Physiol 40, 307-343.
131. Van Schravendijk CF, Foriers A, Van Den Brande JL & Pipeleers DG (1987). Evidence for the presence of type I insulin-like growth factor receptors on rat pancreatic A and B cells. Endocrinology 121, 1784-1788.
132. 2+ in single beta and alpha-cells obtained from pancreatic islets by fluorescence-activated cell sorting. Biochem Biophys Res Comm 166, 813-818.
133. Weir GC, Knowlton SD & Martin DB (1974). Glucagon secretion from the perfused rat pancreas. Studies with glucose and catecholamines. J Appl Physiol 46, 766-771.
134. Weir GC, Samols E, Ramseur R, Day JA & Patel YC (1977). Influence of glucose and glucagon upon somatostatin secretion from isolated perfused canine pancreas. Clin Res 25, 403A.
135. Westermark P & Wilander E (1978). The influence of amyloid deposits on the islet volume in maturity onset diabetes mellitus. Diabetologia 15, 417-421.
136. Westermark P, Wernstedt C, Wilander E, Hayden DW, O'Brien TD & Johanson KH (1987). Amyloid fibrils in human insulinoma and islets of Langerhans of diabetic cat are derived from a neuropeptide-like protein also present in normal islet cells. Proc Natl Acad Sci U S A 84, 3881-3885.
137. Winder WW, Hickson RC, Hagberg JM, Ehsani AA & McLane JA (1979). Training-induced changes in hormonal and metabolic responses to submaximal exercise. J Appl Physiol 46, 766-771.
138. Winkler H & Fischer-Colbrie R (1992). The chromogranins A and B: the first 25 years and future perspectives. Neuroscience 49, 497-528.
139. Wollheim CB (2000). β-Cell mitochondria in the regulation of insulin secretion: a new culprit in type II diabetes. Diabetologia 43, 265-277.
140. Yokota I & Shima K (1998). GAD antibody in IDDM. Rinsho Byori 46, 331-337.
141. Zambre Y, Ling Z, Chen MC, Hou X, Woon CW, Culler M, Taylor JE, Coy DH, Van Schravendijk C, Schuit F, Pipeleers DG & Eizirik DL (1999). Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem Pharm 57, 1159-1164.
142. Zinman B, Murray FT, Vranic M, Albisser AM, Leibel BS, McClean PA & Marliss EB (1977). Glucoregulation during moderate exercise in insulin treated diabetics. J Clin Endocrinol Metab 45,